Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market scope & definitions
1.3 Base estimates & working
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Secondary
1.7.1.1 Paid sources
1.7.1.2 Public sources
1.7.2 Primary
Chapter 2 Executive Summary
2.1 Cancer diagnostics industry 3600 synopsis, 2018-2032
2.1.1 Business trends
2.1.2 Application trends
2.1.3 Cancer type rends
2.1.4 End-use trends
2.1.5 Regional trends
Chapter 3 Cancer Diagnostics Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rising prevalence of cancer globally
3.3.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
3.3.1.3 Growing number of diagnostic laboratories in developed countries
3.3.1.4 Technology advancements in developed countries
3.3.2 Industry pitfalls & challenges
3.3.2.1 High capital investment coupled with high costs associated with diagnostic imaging systems
3.3.2.2 Risk related with high radiation exposure affecting use of CT scanner
3.4 Growth potential analysis
3.4.1 By application
3.4.2 By cancer type
3.4.3 By end-use
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis
4.3 Strategic dashboard
Chapter 5 Cancer Diagnostics Market, By Application
5.1 Key application trends
5.2 Tumor biomarkers tests
5.2.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.3 Imaging
5.3.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.3.2 Ultrasound and radiology
5.3.2.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.3.3 Mammography
5.3.3.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.3.4 MRI scan
5.3.4.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.3.5 PET scan
5.3.5.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.3.6 CT scan
5.3.6.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.3.7 SPECT & others
5.3.7.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.4 Biopsy
5.4.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.5 Liquid biopsy
5.5.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.6 Immunohistochemistry
5.6.1 Market estimates and forecast, 2018 – 2032 (USD Million)
5.7 In situ hybridization
5.7.1 Market estimates and forecast, 2018 – 2032 (USD Million)
Chapter 6 Cancer Diagnostics Market, By Cancer Type
6.1 Key cancer type trend
6.2 Bladder cancer
6.2.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.3 Breast cancer
6.3.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.4 Colon and rectal cancer
6.4.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.5 Endometrial cancer
6.5.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.6 Kidney cancer
6.6.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.7 Leukemia
6.7.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.8 Liver-lung cancer
6.8.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.9 Melanoma
6.9.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.10 Non-Hodgkin lymphoma
6.10.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.11 Pancreatic cancer
6.11.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.12 Prostate cancer
6.12.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.13 Thyroid cancer
6.13.1 Market estimates and forecast, 2018 – 2032 (USD Million)
6.14 Others
6.14.1 Market estimates and forecast, 2018 – 2032 (USD Million)
Chapter 7 Cancer Diagnostics Market, By End-use
7.1 Key end-use trend
7.2 Hospitals
7.2.1 Market size, by region, 2018 – 2032 (USD Million)
7.3 Diagnostic laboratories
7.3.1 Market size, by region, 2018 – 2032 (USD Million)
7.4 Diagnostic imaging centers
7.4.1 Market size, by region, 2018 – 2032 (USD Million)
7.5 Cancer research institutes
7.5.1 Market size, by region, 2018 – 2032 (USD Million)
Chapter 8 Cancer Diagnostics Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Russia
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 AB Sciex Pte. Ltd
9.3 Agilent Technologies Inc
9.4 Becton, Dickinson and Company
9.5 Biocare Medical LLC
9.6 Biocartis
9.7 BioMerieux SA
9.8 Bio-Rad Laboratories
9.9 Cancer Genetics Inc
9.10 GE Healthcare
9.11 Hologic Inc
9.12 Janssen Diagnostics LLC (Johnson & Johnson)
9.13 Leica Biosystem Nussloch GmbH (Danaher Corporation)
9.14 Myriad Genetics, Inc
9.15 Qiagen N.V
9.16 F-Hoffmann-La Roche Ltd
9.17 Siemens Healthineers
9.18 Sysmex Corporation
9.19 Thermo Fischer Scientific
